G
Genelux Corporation (GNLX)
NCM – Real Time Price. Currency in USD
2.97
+0.07 (2.41%)
At close: May 12, 2026, 4:00 PM EDT
2.91
-0.06 (-2.02%)
After-hours: May 12, 2026, 6:52 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.97
+0.07 (2.41%)
At close: May 12, 2026, 4:00 PM EDT
2.91
-0.06 (-2.02%)
After-hours: May 12, 2026, 6:52 PM EDT
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
| Name | Position |
|---|---|
| Dr. Jason B. Litten M.D. | Chief Medical Officer |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer |
| Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development |
| Mr. Eric Groen J.D. | General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development |
| Mr. Matthew Pulisic M.B.A. | CFO and Principal Financial & Accounting Officer |
| Mr. Ralph Smalling B.Sc. | VP & Head of Regulatory Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 10-Q | form10-q.htm |
| 2026-04-29 | DEFA14A | formdefa14a.htm |
| 2026-04-29 | DEF 14A | formdef14a.htm |
| 2026-03-19 | S-8 | forms-8.htm |
| 2026-02-02 | 8-K | form8-k.htm |
| 2026-01-08 | 8-K | form8-k.htm |
| 2026-01-05 | 8-K | form8-k.htm |
| 2026-01-02 | 8-K | form8-k.htm |
| 2025-11-05 | 10-Q | form10-q.htm |
| 2025-09-03 | 8-K | form8-k.htm |
| Mr. Thomas D. Zindrick J.D. | Chairman, CEO & President |